How did chronic hepatitis C impact costs related to hospital health care in France in 2009?

Clinics and Research in Hepatology and Gastroenterology

Volumn 37, Issue 4, 2013, Pages 365-372

  Rotily, Michel ^a   Vainchtock, Alexandre ^a   Jouaneton, Baptiste ^a   Wartelle Bladou, Claire ^b   Abergel, Armand ^c  

^a HEVA   (France)

^b CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; RIBAVIRIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; DATA BASE; ECHOGRAPHY; FEMALE; FRANCE; HEPATITIS C; HOSPITAL COST; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; INFANT; LENGTH OF STAY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; SCHOOL CHILD; SOCIAL SECURITY;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; FEMALE; FRANCE; HEALTH CARE COSTS; HEPATITIS C, CHRONIC; HOSPITALIZATION; HUMANS; INFANT; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84883554302     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2012.11.004     Document Type: Article

References (23)

1. Cornberg M., Razavi H.A., Alberti A., et al. A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 2011, 31(Suppl. 2):30-60.
2. World Health Organization: Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat 1999, 6(1):35-47.
3. Mühlberger N., Schwarzer R., Lettmeier B., et al. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence, morbidity, and mortality. BMC Public Health 2009, 9:34.
4. Asselah T., Marcellin P. New direct-acting antivirals' combination for the treatment of chronic hepatitis C. Liver Int 2011, 31(Suppl. 1):68-77.
5. Institut de veille sanitaire. L'épidémiologie des hépatites B et C en France. Bull Epidemiol Hebd 2009; 20-21: 195. Disponible à: [consulté le 30/09/2011]. http://www.invs.sante.fr/beh/2009/20_21/beh_20_21_2009.pdf.
6. Deuffic-Beurban S., Mathurin P., et al. Impact of hepatitis C triple therapy availability upon the number of patients treated and associated costs in France: a model-based analysis. Gut 2012, 61:290-296.
7. Deuffic-Beurban S., Mathurin P., Valleron A.J. Modelling the past, current and future HCV burden in France: detailed analysis and perspectives. Stat Methods Med Res 2009, 18(3):233-252.
8. Vallier N., Weill A., Salanave B., et al. Cost of thirty long-term diseases for beneficiaries of the French general health insurance scheme in 2004. Prat Organ Soins 2006, 37(4):267-283.
9. Heathcote J., Main J. Treatment of hepatitis C. J Viral Hepat 2005, 12(3):223-235.
10. Brouard C., Pradat P., Delarocque-Astagneau E., et al. Epidemiological characteristics and medical follow-up of 61 patients with acute hepatitis C identified through the hepatitis C surveillance system in France. Epidemol Infect 2008, 136:988-996.
11. Al-Freah M.A., Zeino Z., Heneghan M.A., et al. Management of hepatitis C in patients with chronic kidney disease. Curr Gastroenterol Rep 2012, 14(1):78-86.
12. Botté C., Janot C. Epidemiology of HCV infection in the general population and in blood transfusion. Nephrol Dial Transplant 1996, 11(Suppl. 4):19-21.
13. Rusu-Dragos S, Haury B, Guignon N, et al. Le recours aux soins hospitaliers pour hépatite C chronique. Direction de la Recherche, des études, de l'évaluation et des statistiques. Études et résultats no 2, 1999.
14. Guignon N, Haury B. La prise en charge et les conditions de vie des patients atteints d'une hépatite chronique. Direction de la recherche, des études, de l'évaluation et des statistiques. Études et résultats no 368, 2005.
15. Surveillance nationale de l'hépatite C à partir des pÔles de référence volontaires. Publié le 11/09/2007 - Dernière mise à jour le 22/07/2009. Disponible à: [consulté le 30/09/2011]. http://www.invs.sante.fr/fr/Dossiers-thematiques/Maladies-infectieuses/Hepatitesvirales/Hepatite-C/Surveillance-nationale-de-l-hepatite-C-a-partir-des-poles-de-referencevolontaires.
16. McAdam-Marx C., McGarry L.J., Hane C.A., et al. All-cause and incremental per patient per year cost associated with chronic hepatitis C virus and associated liver complications in the united states: a managed care perspective. J Manag Care Pharm 2011, 17(7):531-546.
17. Cadranel J.F., Rufat P., Degos F. Practices of transcutaneous liver biopsies in France. Results of a retrospective nationwide study. Gastroenterol Clin Biol 2001, 25(1):77-80.
18. Cadranel J.F., Rufat P., Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000, 32:477-481.
19. El Khoury A.C., Wallace C., Klimack W.K., Razavi H. Economic burden of hepatitis C-associated diseases: Europe, Asia Pacific, and the Americas. J Med Econ 2012, 15(5):887-896. 10.3111/13696998.2012.681332.
20. El Khoury A.C., Klimack W.K., Wallace C., et al. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat 2012, 19(3):153-160.
21. Bennett W.G., Inoue Y., Beck J.R., et al. Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C. Ann Int Med 1997, 127(10):855-865.
22. Grieve R., Roberts J., Wright M., et al. Cost effectiveness of interferon alpha or peginterferon alpha with ribavirin for histologically mild chronic hepatitis C. Gut 2006, 55(9):1332-1338.
23. Gordon S.C., Pockros P.J., Terrault N.A., et al. Disease burden in patients with chronic hepatitis C infection in a United States private health insurance claims database analysis form 2003 to 2010 (abstract 1727). Hepatology 2011, 54(4 (Suppl.)):1175A.